2008: IT budgets to fall?

Euro If the pundits are right, IT budgets will be smaller next year. Or, to put it more correctly, the percent increase for 2008 over 2007 will be less than the percent increase for 2007 over 2006. Are you still with me?

As an example, take the recent article by John Soat of Information Week, who cites two separate surveys involving CIOs. Both predict smaller budget increases for 2008. Mind you, this is across all industries and it's not clear what will happen in the Biopharma sector.

We can guess, however, that based on the somewhat dismal performance of most pharma and some biotech companies, CEOs will be looking for savings wherever they can be found. And that includes IT.

From my perspective, this is quite unfortunate since I am convinced that our industry has squandered countless opportunities to leverage information technologies to improve both day-to-day operations and improve the R&D pipeline. If you want examples, I'll give you several:

  • document management and electronic publishing
  • data management and exploration
  • electronic data collection (EDC)
  • clinical trial management
  • master data management

Now, you may be saying: "Is this guy nuts? These are the areas where we have made the most progress!"

And no, I'm not nuts. These are great examples where lots of time and money have been wasted or investments underperformed. Despite glowing reports at DIA meetings and other venues, the reality is that we still don't know how to properly leverage IT.

I'll offer just a few reasons why our IT dollars/euros don't get us the returns we need:

  1. Lack of resolve and leadership to change course;
  2. Continued disconnect between the business community and the IT organization;
  3. Missing or half-baked strategy for improving productivity;
  4. Cowardly management disguised as management by consensus;
  5. Focus on regulatory compliance rather than operating efficiency;
  6. Failure to create a learning and innovative organization;
  7. Over-reliance on selecting technology rather than setting strategy that drives technology.

So, it's possible that we don't actually need to increase the IT budget. Maybe it would be enough to just stop wasting it.

Biopharm IT Leaders - The Infoweek 500

Infoweekit00 The 19th Annual Information Week 500 list has been published.

Here, we will only concentrate on the Biotechnology and Pharmaceutical companies that made the list.

As the publication states, "to be ranked, companies with at least $500 million in annual revenue are asked to complete a qualifying application that examines business technology strategies. The application contains a quantitative section on technology initiatives and priorities, and a qualitative section of essay questions. The responses to these two sections are evaluated, weighted, and combined into a total score to rank the companies."

The following Biotech and Pharma companies made the list:

  • BD Biosciences
  • Beckman Coulter
  • Eli Lilly
  • Genzyme
  • GSK
  • Merck
  • Pfizer
  • Roche Diagnostics
  • Schering Plough
  • Solvay
  • Thermo Fisher Scientific
  • Wyeth

Of these, only three made it into the top 250 list. These are:

  • Eli Lilly - #50
  • Wyeth - #59
  • Roche Diagnostics - #231

Read on to learn a bit more...

Continue reading "Biopharm IT Leaders - The Infoweek 500" »

Biopharma RFID Market Projections

In Brief

According to a recent article in InPharma Technologist, "the take up of smart tags in the [USA] pharmaceutical industry is already booming and the pharma sector is now the second largest adopter of RFID technology, with 18 per cent of suppliers and 14 per cent of customers in this field now piloting or using RFID."

In addition, "the market for RFID tags in US healthcare is predicted to explode from $90m (€70m) in 2006 to $2.1bn in 2016."

While this article paints a rosy picture for RFID adoption, this web site has previously reviewed the many issues that could prevent as fast a growth as implied by these projections.

Another posting lists the key product suppliers in this arena.

The Laszlo Letter

FiftyClinical Trials Top 50

Presenting the 1st Annual Clinical Trials Top 50 List!

If you are a consulting firm, software vendor, CRO or other service provider, it is likely that you are trying to determine where to focus your energies. If clinical research is an important revenue source for your business, you should find these ranking useful.

To all others interested in life sciences, the rankings will at least be interesting.

If a lot of you agree, I will make this an annual topic.

So read on...

Continue reading "The Laszlo Letter" »

Revenues from DTC vs. Detailing

Leave it to an outsider to come up with this one:

"Pharma can receive twice as much revenue from detailing than from DTC. For every dollar spent detailing, firms should expect about $10 in revenues. The return from DTC advertising is more in the range of $5 to $6."

Source: Sridhar Narayanan, Assistant Professor of Marketing, Stanford Graduate School of Business

As reported in Pharmaceutical Executive, February 2007

The Fortune Global 500 - Where is Pharma?

The July 24, 2006 issue of Fortune magazine lists the 500 largest global public companies. So, I was wondering how the pharmaceutical industry fares on this list. Perhaps you will find this interesting too.

Continue reading "The Fortune Global 500 - Where is Pharma?" »